There’s strength in the stories of people living with rare diseases.

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency

Pharming Group N.V. announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetable included in the CHMP Day 180 Second LoOI, and considering the CHMP’s decision to reschedule the Ad-Hoc Expert Group (AEG) meeting to the end of November, Pharming now expects the CHMP to issue its opinion on the leniolisib MAA in the first quarter of 2024.

Pharming Group N.V. announces 14 poster presentations by the Company or its collaborators regarding leniolisib and RUCONEST® at the International Primary Immunodeficiencies Congress (IPIC) and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in November.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of November:

Pharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2023.

Pharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.

Pharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.

Pharming shortlisted in two categories, including “Biotech Company of the Year” and “Best New Drug”